The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Open accessAbstract
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study. METHODS: We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (> or =10 mg per week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate. Responses defined according to the criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses). RESULTS: At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent). In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P< or =0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P< or =0.004). All ACR responses were maintained at week 48 in the rituximab-methotrexate group. The majority of adverse events occurred with the first rituximab infusion: at 24 weeks, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups. Peripheral-blood immunoglobulin concentrations remained within normal ranges. CONCLUSIONS: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease”
From The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer (2015) · cites this paper as Edwards et al., 2004
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,248
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B. J., Fürst, D. E., Goldsmith, C. H., Kieszak, S. M., Lightfoot, R. W., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,639
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J., & Cambridge, G. (2001) · Lara D. Veeken · doi:10.1093/rheumatology/40.2.205 · Cited by 525
Self-citationClinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 344
Self-citationvan Gestel, A. M., Anderson, J. J., van Riel, P. L. C. M., Boers, M., HAAGSMA, C. J., Rich, B., Wells, G. A., Lange, M., & Felson, D. T. (1999) · PubMed · Cited by 250
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, E., Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
The role of B cells in rheumatoid arthritis
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Research works printed but not linked: 3
- Van Gestel AM, 1999, J Rheumatol, 26, 705
- Tighe H, Carson DA. Rheumatoid factors. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:241-9.
- McLaughlin P, 1999, Semin Oncol, 26, 79
Cited by
Sorted by citations
Items 401–500 of 1,000
Treatment of retinal vasculitis in Behçet's disease with rituximab
Sadreddini, S., Noshad, H., Molaeefard, M., & Noshad, R. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0057-9 · Cited by 105
Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases
Engel, P., Gómez-Puerta, J. A., Ramos‐Casals, M., Lozano, F., & Bosch, X. (2011) · Pharmacological Reviews · doi:10.1124/pr.109.002006 · Cited by 107
Outcomes of rituximab therapy in refractory lupus: A meta-analysis
Alshaiki, F., Obaid, E. F., Almuallim, A. A., Taha, R., El-Haddad, H., & Almoallim, H. M. (2018) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2018.17096 · Cited by 107
B cell checkpoints in autoimmune rheumatic diseases
Rubin, S. J. S., Bloom, M. S., & Robinson, W. H. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0211-0 · Cited by 109
B Cells Amplify IFN-γ Production By T Cells via a TNF-α-Mediated Mechanism
Menard, L. C., Minns, L. A., Darche, S., Mielcarz, D. W., Foureau, D., Roos, D. S., Dzierszinski, F. S., Kasper, L. H., & Buzoni–Gatel, D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4857 · Cited by 107
Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge
Luger, E., Fokuhl, V., Wegmann, M., Abram, M., Tillack, K., Achatz, G., Manz, R. A., Worm, M., Radbruch, A., & Renz, H. E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.047 · Cited by 107
François, H., Daugas, É., BENSMAN, A., & Ronco, P. M. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.10.015 · Cited by 107
Puéchal, X., Gottenberg, J., Berthelot, J., Gossec, L., Meyer, O., Morel, J., Wendling, D., Bandt, M. D., Houvenagel, É., Jamard, B., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20689 · Cited by 107
de la Torre, I., Leandro, M. J., Valor, L., Becerra-Fernández, E., Edwards, J., & Cambridge, G. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/ker417 · Cited by 106
Self-citationTernant, D., Bejan‐Angoulvant, T., Passot, C., Mulleman, D., & Paintaud, G. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0296-9 · Cited by 106
B-Cell-Targeted Therapy for Systemic Lupus Erythematosus
Sabahi, R., & Anolik, J. H. (2006) · Drugs · doi:10.2165/00003495-200666150-00004 · Cited by 106
Rheumatoid factors: what's new?
Westwood, O. M. R., Nelson, P. N., & Hay, F. C. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kei228 · Cited by 106
Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
Agarwal, S. K. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.s9-b.s14 · Cited by 105
Utility of Influenza Vaccination for Oncology Patients
Pollyea, D. A., Brown, J. W., & Horning, S. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6908 · Cited by 105
Rituximab for Rheumatoid Arthritis
Cohen, M. D., & Keystone, E. C. (2015) · Rheumatology and Therapy · doi:10.1007/s40744-015-0016-9 · Cited by 105
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance
Harbers, S. O., Crocker, A., Catalano, G., D’Agati, V. D., Jung, S., Desai, D. D., & Clynes, R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29470 · Cited by 105
Rituximab in relapsing Graves' disease, a phase II study
Heemstra, K. A., Toes, R. E. M., Sepers, J. M., Pereira, A. M., Corssmit, E. P. M., Huizinga, T. W. J., Romijn, J. A., & Smit, J. W. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0084 · Cited by 105
Biologic therapies for inflammatory eye disease
Lim, L. L., Suhler, E. B., & Smith, J. R. (2006) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2006.01225.x · Cited by 104
Duroux-Richard, I., Pers, Y., Fabre, S., Ammari, M., Baeten, D., Cartron, G., Touitou, I., Jørgensen, C., & Apparailly, F. (2014) · Mediators of Inflammation · doi:10.1155/2014/342524 · Cited by 103
Robeson, K. R., Kumar, A., Keung, B., DiCapua, D. B., Grodinsky, E., Patwa, H. S., Stathopoulos, P., Goldstein, J. M., O’Connor, K. C., & Nowak, R. J. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4190 · Cited by 103
Sakagami, T., Beck, D. C., Uchida, K., Suzuki, T., Carey, B. C., Nakata, K., Keller, G. L., Wood, R. E., Wert, S. E., Ikegami, M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0008oc · Cited by 103
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Zaja, F. F., Battista, M. L., Pirrotta, M. T., Palmieri, S., Montagna, M., Vianelli, N., Marin, L., Cavallin, M., Bocchia, M., Defina, M., et al. (2008) · Haematologica · doi:10.3324/haematol.12206 · Cited by 103
Rituximab therapy in autoimmune pulmonary alveolar proteinosis
Borie, R., Debray, M., Laine, C. M., Aubier, M., & Crestani, B. (2009) · European Respiratory Journal · doi:10.1183/09031936.00160908 · Cited by 103
Pijpe, J., van Imhoff, G. W., Vissink, A., van der Wal, J. E., Kluin, P. M., Spijkervet, F. K. L., Kallenberg, C. G. M., & Bootsma, H. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030684 · Cited by 103
Anaya, J., Ramírez-Santana, C., Alzate-Vinasco, M. A., Molano‐González, N., & Rojas‐Villarraga, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00139 · Cited by 113
B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus
Eisenberg, R. A., & Albert, D. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0042 · Cited by 101
Doyle, T. J., Dhillon, N., Madan, R., Cabral, F., Fletcher, E. A., Koontz, D. C., Aggarwal, R., Osorio, J. C., Rosas, I. O., Oddis, C. V., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170541 · Cited by 102
Hedrich, W. D., Fandy, T. E., Ashour, H. M., Wang, H., & Hassan, H. E. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0619-0 · Cited by 103
Pathogenic Citrulline‐Multispecific B Cell Receptor Clades in Rheumatoid Arthritis
Titcombe, P. J., Wigerblad, G., Sippl, N., Zhang, N., Shmagel, A., Sahlström, P., Zhang, Y., Barsness, L. O., Ghodke‐Puranik, Y., Baharpoor, A., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40590 · Cited by 102
Adult stem cells in the treatment of autoimmune diseases
van Laar, J. M., & Tyndall, A. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel158 · Cited by 102
Cantini, F., Niccoli, L., & Goletti, D. (2014) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.140103 · Cited by 91
Reddy, V. R., Cambridge, G., Isenberg, D. A., Glennie, M. J., Cragg, M. S., & Leandro, M. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39167 · Cited by 101
Bellucci, R., Alyea, E. P., Chiaretti, S., Wu, C. J., Zorn, E., Weller, E. A., Wu, B., Canning, C. M., Schlossman, R. L., Munshi, N. C., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4463 · Cited by 101
New treatments for SLE: cell-depleting and anti-cytokine therapies
Anolik, J. H., & Aringer, M. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.05.006 · Cited by 101
B cell–directed therapies for autoimmune disease and correlates of disease response and relapse
Levesque, M. C., & Clair, E. W. S. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.030 · Cited by 100
Bergman, G., Hochberg, M., Boers, M., Wintfeld, N., Kielhorn, A., & Jansen, J. (2010) · Seminars in Arthritis & Rheumatism · doi:10.1016/j.semarthrit.2009.12.002 · Cited by 109
Shi, Y., Xie, F., Rao, P., Qian, H., Chen, R., Hu, C., Li, D., Mu, D., Zhang, L., Lv, P., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.054 · Cited by 101
Olalekan, S. A., Cao, Y., Hamel, K. M., & Finnegan, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201445036 · Cited by 107
Egawa, H., Ohmori, K., Haga, H., Tsuji, H., Yurugi, K., Miyagawa‐Hayashino, A., Oike, F., Fukuda, A., Yoshizawa, J., Takada, Y., et al. (2007) · Liver Transplantation · doi:10.1002/lt.21092 · Cited by 100
New Therapeutic Horizons for Graves’ Hyperthyroidism
Lane, L. C., Cheetham, T. D., Perros, P., & Pearce, S. H. S. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa022 · Cited by 102
He, J., Zhou, S., Lv, J., & Zhang, H. (2020) · Theranostics · doi:10.7150/thno.49778 · Cited by 106
B cells in rheumatoid arthritis
Bugatti, S., Codullo, V., Caporali, R. F., & Montecucco, C. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.008 · Cited by 99
Liposome‐bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis
Martínez‐Lostao, L., Garcí´a‐Alvarez, F., Basáñez, G., Alegre‐Aguarón, E., Desportes, P., Larrad, L., Naval, J., Martínez‐Lorenzo, M. J., & Anel, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27501 · Cited by 100
Current approaches to treatment of antibody‐mediated rejection
Jordan, S. C., Vo, A. A., Tyan, D. B., Nast, C. C., & Toyoda, M. (2005) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2005.00363.x · Cited by 99
Recent developments in the immunobiology of rheumatoid arthritis
Andersson, A. K., Li, C. L., & Brennan, F. M. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2370 · Cited by 98
Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review
Nevius, E., Gomes, A. C., & Pereira, J. P. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8520-9 · Cited by 100
Current perspective on rituximab in rheumatic diseases
Schioppo, T., & Ingegnoli, F. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s139248 · Cited by 98
Cupi, M. L., Sarra, M., Marafini, I., Monteleone, I., Franzè, E., Ortenzi, A., Colantoni, A., Sica, G. S., Sileri, P., Rosado, M. M., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302238 · Cited by 98
Scleritis: Immunopathogenesis and molecular basis for therapy
Wakefield, D., Girolamo, N. D., THURAU, S. R., Wildner, G., & McCluskey, P. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.004 · Cited by 98
Arlet, J., Dimitri, D., Pagnoux, C., Boyer, O., Maisonobe, T., Authier, F., Bloch‐Queyrat, C., Goulvestre, C., Heshmati, F., Atassi, M., et al. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.03.002 · Cited by 98
Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy
Leandro, M. J., Cooper, N., Cambridge, G., Ehrenstein, M. R., & Edwards, J. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel148 · Cited by 98
Self-citationLeshem, Y. A., Hodak, E., David, M., Anhalt, G. J., & Mimouni, D. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.08.010 · Cited by 97
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
Athni, T. S., & Barmettler, S. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.01.018 · Cited by 108
Killer B lymphocytes: the evidence and the potential
Lundy, S. K. (2009) · Inflammation Research · doi:10.1007/s00011-009-0014-x · Cited by 113
Rituximab for Idiopathic Membranous Nephropathy
Ruggenenti, P. L., Chiurchiu, C. R., Abbate, M., Perna, A., Cravedi, P., Bontempelli, M., & Remuzzi, G. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01080905 · Cited by 97
Rituximab therapy for juvenile-onset systemic lupus erythematosus
Nwobi, O., Abitbol, C. L., Chandar, J. J., Seeherunvong, W., & B, G. Z. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0694-9 · Cited by 97
Therapeutic Decisions in Multiple Sclerosis
Brück, W., Gold, R., Lund, B. T., Oreja‐Guevara, C., Prat, A., Spencer, C. M., Steinman, L., Tintoré, M., Vollmer, T. L., Weber, M. S., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3510 · Cited by 96
TEIXEIRA, V. H., Olaso, R., Martin‐Magniette, M., Lasbleiz, S., Jacq, L., Oliveira, C. R., Hilliquin, P., Gut, I. G., Cornélis, F., & Petit, É. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006803 · Cited by 96
Greenwald, M., Shergy, W. J., Kaine, J., Sweetser, M. T., Gilder, K. M., & Linnik, M. D. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30194 · Cited by 96
Effective therapeutic use of rituximab in refractory Wegener's granulomatosis
Ferraro, A. J., Day, C., Drayson, M. T., & Savage, C. O. S. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh599 · Cited by 96
Effects of rituximab therapy on B cell differentiation and depletion
Bergantini, L., d’Alessandro, M., Cameli, P., Vietri, L., Vagaggini, C., Perrone, A., Sestini, P., Frediani, B., & Bargagli, E. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-04996-7 · Cited by 95
Shimanovich, I., Nitschke, M., Rosé, C., Grabbe, J., & Zillikens, D. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08358.x · Cited by 95
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Whang, J. A., & Chang, B. Y. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.028 · Cited by 95
Successful treatment of refractory anterior scleritis in primary Sjögren's syndrome with rituximab
Ahmadi-Simab, K., Lamprecht, P., Nölle, B., Ai, M., & Gross, W. L. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.027128 · Cited by 95
Monach, P. A., Hueber, W., Kessler, B. M., Tomooka, B. H., BenBarak, M. J., Simmons, B. P., Wright, J., Thornhill, T. S., Monestier, M., Ploegh, H. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908032106 · Cited by 95
Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
Kusumoto, S., Tanaka, Y., Ueda, R., & Mizokami, M. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0331-4 · Cited by 94
Lu, D., McDavid, A., Kongpachith, S., Lingampalli, N., Glanville, J., Ju, C., Gottardo, R., & Robinson, W. H. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40578 · Cited by 93
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases
Kingsmore, K. M., Grammer, A. C., & Lipsky, P. E. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0337-0 · Cited by 97
Scheel, T., Gursche, A., Zacher, J., Häupl, T., & Berek, C. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27767 · Cited by 94
The pharmacokinetics of rituximab following an intravitreal injection
Kim, H., Csaky, K. G., Chan, C., Bungay, P. M., Lutz, R. J., Dedrick, R. L., Yuan, P., Rosenberg, J., Grillo-López, A. J., Wilson, W. H., et al. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.09.018 · Cited by 94
Immunogenicity of rituximab in patients with severe pemphigus
Schmidt, E., Hennig, K., Mengede, C., Zillikens, D., & Kromminga, A. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.05.007 · Cited by 94
Moura, R. A., Quaresma, C., Vieira, A. R., Gonçalves, M. J., Pereira, J. P., Romão, V. C., Martins, N., Canhão, H. M., & Fonseca, J. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182927 · Cited by 93
Proinflammatory CD20 + T cells contribute to CNS-directed autoimmunity
Ochs, J., Nissimov, N., Torke, S., Freier, M., Grondey, K., Koch, J., Klein, M., Feldmann, L., Gudd, C. L. C., Bopp, T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi4632 · Cited by 91
Atkins, S. R., Turesson, C., Myers, J. L., Tazelaar, H. D., Ryu, J. H., Matteson, E. L., & Bongartz, T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21758 · Cited by 93
Blocking of experimental arthritis by cleavage of IgG antibodies in vivo
Nandakumar, K. S., Johansson, B. P., Björck, L., & Holmdahl, R. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22930 · Cited by 93
van Baarsen, L. G. M., Bos, W. H., Rustenburg, F., Kraan, T. C. T. M. V. D. P., Wolbink, G., Dijkmans, B. A. C., van Schaardenburg, D., & Verweij, C. L. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27294 · Cited by 93
Segarra-Medrano, A., Praga, M., Ramos-Terrades, N., Polanco, N., Cargol, I., Gutiérrez-Solís, E., Gomez, M. R., Ronsano, J. B. M., & Camps, J. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06041108 · Cited by 93
Singh, J. A., Hossain, A., Tanjong-Ghogomu, E., Kotb, A., Christensen, R., Mudano, A., Maxwell, L. J., Shah, N. P., Tugwell, P., & Wells, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012183 · Cited by 88
McCarthy, E. M., Sutton, E. J., Nesbit, S., White, J., Parker, B., Jayne, D. R. W., Griffiths, B., Isenberg, D. A., Rahman, A., Gordon, C., et al. (2017) · Rheumatology · doi:10.1093/rheumatology/kex395 · Cited by 96
Teng, Y. K. O., Levarht, E. W. N., Toes, R. E. M., Huizinga, T. W. J., & van Laar, J. M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092791 · Cited by 92
Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases
Williams, R. O., Paleolog, E. M., & Feldmann, M. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.06.001 · Cited by 95
Gurzell, E. A., Teague, H., Harris, M., Clinthorne, J. F., Shaikh, S. R., & Fenton, J. I. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0812394 · Cited by 91
Fassi, D. E., Banga, J. P., Gilbert, J. A., Padoa, C. J., Hegedűs, L. D., & Nielsen, C. H. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.09.007 · Cited by 92
Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children
Ravani, P., Bonanni, A., Rossi, R., Caridi, G., & Ghiggeri, G. M. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08500815 · Cited by 92
Rituximab does not reset defective early B cell tolerance checkpoints
Chamberlain, N., Massad, C., Oe, T., Cantaert, T., Herold, K. C., Meffre, E., & the Type 1 Diabetes TrialNet Pathway to Prevention Study Group (2015) · Journal of Clinical Investigation · doi:10.1172/jci83840 · Cited by 92
New therapies for rheumatoid arthritis
Goldblatt, F., & Isenberg, D. A. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02744.x · Cited by 92
Gabay, C., Riek, M., Scherer, A., & Finckh, A. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev019 · Cited by 91
The SLAM family receptors: Potential therapeutic targets for inflammatory and autoimmune diseases
Dragovich, M. A., & Mor, A. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.018 · Cited by 91
Systemic rheumatic diseases: From biological agents to small molecules.
Sarzi-Puttini, P., Ceribelli, A., Marotto, D., Batticciotto, A., & Atzeni, F. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.12.009 · Cited by 84
McLaughlin, K. A., & Wucherpfennig, K. W. (2008) · Advances in immunology · doi:10.1016/s0065-2776(08)00404-5 · Cited by 93
Autoantibodies in rheumatoid arthritis: a review
Mewar, D., & Wilson, A. G. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.09.002 · Cited by 91
Jackson, A. M., Kraus, E. S., Orandi, B. J., Segev, D. L., Montgomery, R. A., & Zachary, A. A. (2014) · Kidney International · doi:10.1038/ki.2014.261 · Cited by 91
Unchecked CD70 Expression on T Cells Lowers Threshold for T Cell Activation in Rheumatoid Arthritis
Lee, W., Yang, Z., Li, G., Weyand, C. M., & Goronzy, J. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2609 · Cited by 92
Hu, F., Liu, H., Xu, L., Li, Y., Liu, X., Shi, L., Su, Y., Qiu, X., Zhang, X., Yang, Y., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201545784 · Cited by 91
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 104
Cell therapy for autoimmune diseases
Dazzi, F., van Laar, J. M., Cope, A. P., & Tyndall, A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2128 · Cited by 93
CD20‐depleting therapy in autoimmune diseases: from basic research to the clinic
Perosa, F., Prete, M., Racanelli, V., & Dammacco, F. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02207.x · Cited by 90
Rituximab: A promising therapy in systemic lupus erythematosus
Thatayatikom, A., & White, A. J. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.05.006 · Cited by 89
Anolik, J. H., Looney, R. J., Lund, F. E., Randall, T. D., & Sanz, I. (2009) · Immunologic Research · doi:10.1007/s12026-009-8096-7 · Cited by 88
He, X., Yang, Y., Yao, M., Yang, L., Ao, L., Hu, X., Li, Z., Wu, X., Tan, Y. Y., Xing, W., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217798 · Cited by 87
Metadata
- Authors
- Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T.
- Affiliations
- University College London (GB)
- University of Wrocław (PL)
- Roche (United Kingdom) (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-17
- Volume
- 350
- Issue
- 25
- Pages
- 2572-2581
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118994799
- Cited by
- 2,623
- References
- 21
- Citations by year
- 2026: 65 · 2025: 69 · 2024: 76 · 2023: 62 · 2022: 61 · 2021: 85 · 2020: 87 · 2019: 85 · 2018: 103 · 2017: 112 · 2016: 96 · 2015: 103 · 2014: 129 · 2013: 133 · 2012: 133
- FWCI
- 109.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, rituximab, B-cell depletion, cyclophosphamide, methotrexate, combination therapy, adverse events, serious infections, immunoglobulin levels, treatment-resistant rheumatoid arthritis, ACR response criteria, EULAR response criteria, maintenance therapy, relapse prevention, long-term follow-up, drug efficacy
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Arthritis, Rheumatoid, B-Lymphocytes, Bacterial Infections, Cyclophosphamide, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Antirheumatic Agents, Antigens, CD20, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
